ASHP Injectable Drug Information August 2023 Update

This update contains 6 new monographs, 44 revised monographs and 1 discontinued monograph.

New monographs: Ado-Trastuzumab Emtansine; Cetuximab; Coagulation Factor IX (Recombinant); Coagulation Factor VIIa (Recombinant); Isoniazid; Tocilizumab.

Revised monographs: Amoxicillin Sodium; Amphotericin B; Azathioprine Sodium; Caffeine Citrate; Calcium Chloride; Calcium Gluconate; Cefazolin Sodium; Cefotaxime Sodium; Cefotetan Disodium; Cefoxitin Sodium; Ceftazidime; Cefuroxime Sodium; Dexamethasone Sodium Phosphate; Dexmedetomidine Hydrochloride; Diazepam; Dopamine Hydrochloride; Epinephrine Hydrochloride; Erythromycin Lactobionate; Famotidine; Fat Emulsion, Intravenous; Fentanyl Citrate; Fluorouracil; Furosemide; Heparin Sodium; Hydrocortisone Sodium Succinate; Insulin; Ketorolac Tromethamine; Levoleucovorin Calcium; Lorazepam; Methohexital Sodium; Methylprednisolone Sodium Succinate; Midazolam Hydrochloride; Milrinone Lactate; Penicillin G Potassium; Penicillin G Sodium; Piperacillin Sodium-Tazobactam Sodium; Potassium Chloride; Remifentanil Hydrochloride; Remimazolam Besylate; Rifampin; Rocuronium Bromide; Vancomycin Hydrochloride; Vasopressin; Vecuronium Bromide.

Discontinued monograph: Aripiprazole.